secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2022-11-25T23:59:59+00:00
Accession:  0001140361-22-043061
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics raises $7.7M via private placement of units with warrants
-----------------------------------------------------------------------------

- Offered 2,184,950 units at $3.53 each, each unit consisting of one share and two warrants exercisable at $3.28 per share for five-and-a-half years.
- Insiders Chairman Charles Cherington and director Nicholas Singer participated on same terms as other investors.
- Closing expected December 2, 2022; net proceeds to be used for general working capital.
- Warrants exercisable six months after closing, with beneficial ownership limitations of 4.99% (adjustable to 9.99%).
- Securities offered under Section 4(a)(2) and Regulation D; resale registration rights to be filed within 30 days of S-3 eligibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036122043061/0001140361-22-043061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036122043061/brhc10044682_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-043061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer